StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > New interview today

<< Previous

Bullboard Posts

Next >>

Comment by capebretongirlon May 19, 2021 12:28pm

120 Views

Post# 33230428

RE:New interview today

Summary: Tripp expects 60% margins to continue - mostly PCR testing on the covid side. CARE is a profitable business with incoming patients staying for 2-4 years - outreach to friends and at risk family for additional testing. Aristole revenue has already been achieved and will continue this quarter and thereafter. Covid + Aristotle + AVRT will generate additional revenue and he expects AVRT will equal Aristotle in revenue. Instead of working with multiple partners, CARE provides single stop shopping.

Have to say this makes a lot of sense and perhaps given that CARE is already profitable, that revenue will become SZLS' and add to the total number - seems to look good for down the road purposes. Now what we need is a reasonable interface with our current sp.